Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia

Experimental Hematology

Volumn 41, Issue 2, 2013, Pages 172-179

  Bernal, Teresa ^a   Moncada Pazos, ángela ^b   Soria Valles, Clara ^b   Gutiérrez Fernández, Ana ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; DNA; GELATINASE B; MATRIGEL; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CANCER GROWTH; CELL COUNT; CELL INVASION; CELL TRANSFORMATION; CELL VIABILITY; CLINICAL ARTICLE; COHORT ANALYSIS; CONCENTRATION RESPONSE; DNA METHYLATION; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKEMIA CELL LINE; MALE; MMP9 GENE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SECRETORY CELL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTIMETABOLITES; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; CATALYSIS; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; ENZYME INDUCTION; FEMALE; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS, SECOND PRIMARY; PROMOTER REGIONS, GENETIC; RISK;

EID: 84873486938     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.10.005     Document Type: Article

References (42)

1. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
3. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase iii study. Lancet Oncol 2009, 10:223-232.
4. Jiang Y., Dunbar A., Gondek L.P., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113:1315-1325.
5. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(ink4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91:2985-2990.
6. Follo M.Y., Finelli C., Mongiorgi S., et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009, 106:16811-16816.
7. Fandy T.E., Herman J.G., Kerns P., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
8. Braun T., Carvalho G., Coquelle A., et al. Nf-kappab constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006, 107:1156-1165.
9. Fabre C., Grosjean J., Tailler M., et al. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: Nfkappab inhibition in malignant myeloblasts. Cell Cycle 2008, 7:2139-2145.
10. Komashko V.M., Farnham P.J. 5-azacytidine treatment reorganizes genomic histone modification patterns. Epigenetics 2010, 5:3.
11. Simo-Riudalbas L., Melo S.A., Esteller M. Dnmt3b gene amplification predicts resistance to DNA demethylating drugs. Genes Chromosomes Cancer 2011, 50:527-534.
12. Jabbour E., Garcia-Manero G., Batty N., et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010, 116:3830-3834.
13. Prebet T., Gore S.D., Esterni B., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
14. Faderl S., Garcia-Manero G., Estrov Z., et al. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol 2011, 28:2755-2760.
15. Qin T., Castoro R., El Ahdab S., et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PloS One 2011, 6:e23372.
16. Sato N., Maehara N., Su G.H., Goggins M. Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 2003, 95:327-330.
17. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
18. Fanjul-Fernandez M., Folgueras A.R., Cabrera S., Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 2010, 1803:3-19.
19. Moncada-Pazos A., Obaya A.J., Fraga M.F., et al. The adamts12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J Cell Sci 2009, 122:2906-2913.
20. Viloria C.G., Obaya A.J., Moncada-Pazos A., et al. Genetic inactivation of adamts15 metalloprotease in human colorectal cancer. Cancer Res 2009, 69:4926-4934.
21. Ries C., Loher F., Zang C., Ismair M.G., Petrides P.E. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin Cancer Res 1999, 5:1115-1124.
22. Chen K.C., Wang Y.S., Hu C.Y., et al. Oxldl up-regulates microrna-29b, leading to epigenetic modifications of mmp-2/mmp-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 2011, 25:1718-1728.
23. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
24. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
25. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
26. Heissig B., Hattori K., Dias S., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires mmp-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
27. Hatfield K.J., Reikvam H., Bruserud O. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia. Curr Med Chem 2010, 17:4448-4461.
28. Janowska-Wieczorek A., Marquez L.A., Matsuzaki A., et al. Expression of matrix metalloproteinases (mmp-2 and -9) and tissue inhibitors of metalloproteinases (timp-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br J Haematol 1999, 105:402-411.
29. Paupert J., Mansat-De Mas V., Demur C., Salles B., Muller C. Cell-surface mmp-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle 2008, 7:1047-1053.
30. Stefanidakis M., Karjalainen K., Jaalouk D.E., et al. Role of leukemia cell invadosome in extramedullary infiltration. Blood 2009, 114:3008-3017.
31. Lin L.I., Lin D.T., Chang C.J., Lee C.Y., Tang J.L., Tien H.F. Marrow matrix metalloproteinases (mmps) and tissue inhibitors of mmp in acute leukaemia: potential role of mmp-9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemia. Br J Haematol 2002, 117:835-841.
32. Travaglino E., Benatti C., Malcovati L., et al. Biological and clinical relevance of matrix metalloproteinases 2 and 9 in acute myeloid leukaemias and myelodysplastic syndromes. Eur J Haematol 2008, 80:216-226.
33. Snoek-van Beurden P.A., Von den Hoff J.W. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005, 38:73-83.
34. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007, 211:19-26.
35. Chicoine E., Esteve P.O., Robledo O., Van Themsche C., Potworowski E.F., St-Pierre Y. Evidence for the role of promoter methylation in the regulation of mmp-9 gene expression. Biochem Biophys Res Commun 2002, 297:765-772.
36. Liu H.B., Voso M.T., Gumiero D., Duong J., McKendrick J.J., Dear A.E. The anti-leukemic effect of a novel histone deacetylase inhibitor mct-1 and 5-aza-cytidine involves augmentation of nur77 and inhibition of mmp-9 expression. Int J Oncol 2009, 34:573-579.
37. Khan R., Aggerholm A., Hokland P., Hassan M., Hellstrom-Lindberg E. A pharmacodynamic study of 5-azacytidine in the p39 cell line. Exp Hematol 2006, 34:35-43.
38. Khan R., Schmidt-Mende J., Karimi M., et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008, 36:149-157.
39. Choudhry H., Catto J.W. Epigenetic regulation of microrna expression in cancer. Methods Mol Biol 2011, 676:165-184.
40. Wong K.Y., So C.C., Loong F., et al. Epigenetic inactivation of the mir-124-1 in haematological malignancies. PloS One 2011, 6:e19027.
41. Overall C.M., Lopez-Otin C. Strategies for mmp inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002, 2:657-672.
42. Lopez-Otin C., Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat Rev Cancer 2010, 10:278-292.